Parker, Mark; Haycox, Alan; Graves, Jane - In: PharmacoEconomics 29 (2011) 8, pp. 719-730
Background: Many clinical trials that generate evidence on the quality-of-life (QOL) improvements provided by new health technologies do not incorporate a preference-based generic measure, but generate only disease-specific data. However, in order to meet the information needs of regulators such...